Medicare Drug Price Negotiation: What Can We Learn From the 2027 Prices and Their Justifications?

Health Affairs

The Centers for Medicare and Medicaid Services (CMS) must consider certain types of data and research in conducting price negotiations for drugs selected under the Medicare Drug Price Negotiation Program.   

Last November, CMS announced the negotiated prices for the 15 drugs selected for 2027 implementation and recently released the statutorily-required explanations of how the agency arrived at those prices. 

Join Health Affairs Publishing on March 30 for a virtual event featuring Kristi Martin of Highway 136 Consulting and Sarah Emond of the Institute for Clinical and Economic Review. 

Martin and Emond will discuss what we can learn from the 2027 prices and recently published explanations. They will also explore any themes in the factors that CMS prioritizes in the negotiation process, now that two years of such explanations exist.  

Moderated by Senior Editor Laura Tollen, audience members will have an opportunity to ask questions. 

This event is part of Health Affairs Publishing’s Eye on the IRA initiative, which covers news and research about the implementation of the Inflation Reduction Act (IRA) of 2022. The initiative is supported by the National Pharmaceutical Council. 

More Information, How to Register